Biomimetic chromatography a useful tool in the drug discovery process

Advances in Chromatography

Volumn 51, Issue , 2013, Pages 91-125

  Chrysanthakopoulos, Marios ^a   Tsopelas, Fotios ^b   Tsantili Kakoulidou, Anna ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL MEMBRANE;

ARTIFICIAL MEMBRANE; BIOMIMETICS; DRUG DEVELOPMENT; LIQUID CHROMATOGRAPHY; PROCEDURES;

BIOMIMETICS; CHROMATOGRAPHY, LIQUID; DRUG DISCOVERY; MEMBRANES, ARTIFICIAL;

EID: 84928755653     PISSN: 00652415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (189)

1. I. Kola, J. Landis, "Can the pharmaceutical industry reduce attrition rates?" Nature Rev. Drug Discovery 3 (2004) 711-715.
2. G. Gaviraghi, R.J. Barnaby, M. Pellegatti, "Pharmacokinetic challenges in lead optimization, " In: B. Testa, H. van de Waterbeemd, G. Folkers, R. Guy (Eds.), Pharmacokinetic Optimization in Drug Research, Verlag Helvetica Chimica Acta: Zürich and Wiley-VCH, Weinheim, 2001, pp. 3-14.
3. T. Kennedy, "Managing the drug discovery/development interface, " Drug Discov. Today 2 (1997) 436-444.
4. B. Testa, G. Vistoli, A. Pedretti, "Musings on ADME predictions and structure-activity relations, " Chem. Biodivers. 2 (2005) 1411-1427.
5. M.C. Rogge, D.R. Taft, "Preclinical drug development, " In: J. Swarbrick (Ed.), Drugs and the Pharmaceutical Sciences, 2nd ed., Vol. 187, Informa Healthcare Publications, USA, 2010.
6. D.A. Smith, H. van de Waterbeemd, "Pharmacokinetics and metabolism in early drug discovery, " Curr. Opin. Chem. Biol. 4 (1999) 373-378.
7. H. van de Waterbeemd, D.A. Smith, K. Beaumont, D.K. Walker, "Property-based design: Optimization of drug absorption and pharmacokinetics, " J. Med. Chem. 44 (2001) 1-21.
8. H. van de Waterbeemd, B.C. Jones, "Predicting oral absorption and bioavailability, " Prog. Med. Chem. 41 (2003) 1-59.
9. T.J. Carlson, M.D. Segall, "Predictive, computational models of ADME properties, " Curr. Drug Disc. (March) (2002) 34-36.
10. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, " Adv. Drug Deliv. 23 (1997) 3-25.
11. G. Camenish, G. Folkers, H. van de Waterbeemd, "Review of theoretical passive drug absorption models: Historical background, recent developments and limitations, " Pharm. Acta Helv. 71 (1996) 309-327.
12. C. Hansch, J.P. Björkroth, A. Leo, "Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design, " J. Pharm. Sci. 76 (1987) 663-687.
13. S.H. Yalkowski, S.C. Valvani, "Solubility and partitioning I: Solubility of nonelectrolytes in water, " J. Pharm. Sci. 69 (1980) 912-922.
14. G. Colmenarejo, A. Alvarez-Pedraglio, J.-L. Lavandera, "Chemoinformatic models to predict binding affinities to human serum albumin, " J. Med. Chem. 44 (2001) 4370-4378.
15. A. Leo, D. Hoekman, "Calculating log P(oct) with no missing fragments; the problem of estimating new interaction parameters, " Perspect. Drug Discov. Design 18 (2000) 19-38.
16. R.F. Rekker, R. Mannhold (Eds.), Calculation of Drug Lipophilicity, Wiley-VCH, Weinheim, 1992.
17. A.K Ghose, G.M Crippen, "Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. I. Partition coefficients as a measure of hydrophobicity, " J. Comput. Chem. 7 (1986) 565-577.
18. W.M. Meylan, P.H. Howard, "Atom/fragment contribution method for estimating octanol-water partition coefficients, " J. Pharm. Sci. 84 (1995) 83-92.
19. R. Mannhold, "Calculation of lipophilicity: A classification of methods, " In: B. Testa, S.D. Kramer, H. Wunderli-Allenspach, G. Folkers (Eds.), Pharmacokinetic Profiling in Drug Research, Wiley, VCH, Zurich, 2006, pp. 333-352.
20. H. van de Waterbeemd, "Which in vitro screens guide the prediction of oral absorption and volume of distribution?" Basic Clin. Pharmacol. Toxicol. 96 (2005) 162-166.
21. S. Yee, "In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth, " Pharm. Res. 14 (1997) 763-766.
22. H.H. Usansky, P.J. Sinko, "Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: Model development and evaluation and derivation of analytical solutions for ka and Fa, " J. Pharm. Exp. Ther. 314 (2005) 391-399.
23. V.E. Thiel-Demby, J.E. Humphreys, L.A. St John Williams, H.M. Ellens, N. Shah, A.D. Ayrton, J.W. Polli, "Biopharmaceutics classification system: Validation and learnings of an in vitro permeability assay, " Mol. Pharm. 6 (2009) 11-18.
24. D.A. Volpe, "Variability in Caco-2 and MDCK cell-based intestinal permeability assays, " J. Pharm. Sci. 97 (2008) 712-725.
25. B. Faller, "Artificial membrane assays to assess permeability, " Curr. Drug Metab. 9 (2008) 886-892.
26. H. Wan, M. Rehngren, F. Giodanetto, F. Bergstrom, A. Tunek, "High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery, " J. Med. Chem. 50 (2007) 4606-4615.
27. G.L. Trainor, "The importance of plasma protein binding in drug discovery, " Expert Opin. Drug Discov. 2 (2007) 51-64.
28. K. Ito, T. Iwatsubo, S. Kanamitsu, Y. Nakajima, Y. Sugiyama, "Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism together with binding and transport, " Ann. Rev. Pharmacol. Toxicol. 38 (1998) 461-499.
29. M. Rowley, J.J. Kulagowski, A.P. Watt, D. Rathbone, G.I. Stevenson, R.W. Carling, R. Baker, et al., "Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDAreceptor antagonists, " J. Med. Chem. 40 (1997) 4053-4068.
30. P.E. Rolan, "Plasma protein binding displacement interactions-Why are they regarded as clinically important?" Br. J. Clin. Pharmacol. 37 (1994) 125-128.
31. H. Wang, H. Zou, Z. Zhang, "Multi-site binding of fenoprofen to human serum albumin studied by a combined technique of microdialysis with high performance liquid chromatography, " Biomed. Chromatogr. 12 (1998) 4-7.
32. R.D. Saiakhov, L.R. Stefan, G. Klopman, "Multiple computer-automated structure evaluation model of the plasma protein binding affinity of diverse drugs, " Perspect. Drug Discov. Des. 19 (2000) 133-155.
33. N.A. Kratochwil, W. Huber, F. Müller, M. Kansy, P.R. Gerber, "Predicting plasma protein binding of drugs: A new approach, " Biochem. Pharmacol. 64 (2002) 1355-1374.
34. F. Barbato, C. Carpentiero, L. Grumetto, M.I. La Rotonda, "Enantioselective retention of β-blocking agents on human serum albumin and α1-acid glycoprotein HPLC columns: Relationships with different scales of lipophilicity, " Eur. J. Pharm. Sci. 38 (2009) 472-478.
35. R.H. McMenamy, J.L. Oncley, "The specific binding of L-tryptophan to serum albumin, " J. Biol. Chem. 233 (1958) 1436-1447.
36. W.E. Muller, In: I.W. Wainer, D.E. Drayer (Eds.), Drug Stereochemistry: Analytical Methods and Pharmacology, Marcel Dekker, New York, 1988, p. 408.
37. E. Domenici, C. Bertucci, P. Salvadori, S. Motellier, I.W. Wainer, "Immobilized serum albumin: Rapid HPLC probe of stereoselective protein-binding interactions, " Chirality 2 (1990) 263-268.
38. T. Braumann, G. Wber, L.H. Grimme, "Quantitative structure-activity relationships for herbicides. Reversed-phase liquid chromatographic retention parameter, log k(w), versus liquid-liquid partition coefficient as a model of the hydrophobicity of phenylureas, s-triazines and phenoxycarbonic acid derivatives, " J. Chromatogr. 261 (1983) 329-343.
39. J.G. Dorsey, M.G. Khaledi, "Hydrophobicity estimations by reversed-phase liquid chromatography. Implications for biological partitioning processes, " J. Chromatogr. A 656 (1993) 485-499.
40. F. Lombardo, M.Y. Shalaeva, K.A. Tupper, F. Gao, "ElogDoct: A tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds, " J. Med. Chem. 44 (2001) 2490-2497.
41. X. Liu, H. Tanaka, A. Yamauchi, B. Testa, H. Chuman, "Determination of lipophilicity by reversed-phase high-performance liquid chromatography: Influence of 1-octanol in the mobile phase, " J. Chromatogr. A 1091 (2005) 51.
42. C. Giaginis, S. Theocharis, A. Tsantili-Kakoulidou, "Contribution to the standardization of the chromatographic conditions for the lipophilicity assessment of neutral and basic drugs, " Anal. Chim. Acta 573-574 (2006) 311-318.
43. C. Giaginis, S. Theocharis, A. Tsantili-Kakoulidou, "Octanol/water partitioning simulation by reversed phase HPLC for structurally diverse acidic drugs: Effect of octanol as mobile phase additive, " J. Chromatogr. A 1166 (2007) 116-125.
44. C. Giaginis, A. Tsantili-Kakoulidou, "The current state of the art in HPLC methodology for lipophilicity assessment of basic drugs. A review, " J. Liq. Chromatogr. & Relat. Technol. 31 (2008) 79-96.
45. C. Giaginis, A. Tsantili-Kakoulidou, "Alternative measures of lipophilicity. From octanol-water partitioning to IAM retention, " J. Pharm. Sci. 97 (2008) 2984-3004.
46. R.R. Walters, "Affinity chromatography, " Anal. Chem. 57 (1985) 1099-1114.
47. D.S. Hage, In: E. Katz, R. Eksteen, N. Miller (Eds.), Handbook of HPLC, Mercel Dekker, New York, 1998, Chapter 13.
48. A. Leo, C. Hansch, D. Elkins, "Partition coefficients and their uses, " Chem. Rev. 71 (1971) 525-616.
49. C. Hansch, A. Leo, D. Hoekman D, Fundamentals and Applications in Chemistry and Biology in Exploring QSAR, American Chemical Society, Washington, DC, 1995.
50. H. van de Waterbeemd, B. Testa, "The parametrization of lipophilicity and other structural properties in drug design, " In: B. Testa (Ed.), Advances in Drug Research, Vol. 16, Academic Press, New York, 1987, pp. 85-227.
51. R.P. Mason, D.G. Rhodes, L.G. Herbette, "Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes, " J. Med. Chem. 34 (1991) 870-877.
52. K. Balon, B.W. Mueller, B.U. Riebesehl, "Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption, " Pharm. Res. 16 (1999) 882-888.
53. S. Krämer, "Liposomes/water partitioning: Theory techniques and applications, " In: B. Testa, H. van de Waterbeemd, G. Folkers, R. Guy (Eds.), Pharmacokinetic Optimization in Drug Research, Verlag Helvetica ChimicaActa, Zürich and Wiley-VCH, Weinheim, 2001.
54. G.V. Betageri, J.A. Rogers, "The liposomes as a distribution model in QSAR studies, " Int. J. Pharm. 46 (1988) 95-102.
55. L. De Young, K.A. Dill, "Solute partitioning into lipid bilayer membranes, " Biochemistry 27 (1988) 5281-5289.
56. C. Pidgeon, S. Ong, H. Liu, X. Qiu, M. Pidgeon, A.H. Dantzig, J. Munroe, et al., "IAM chromatography: An in vitro screen for predicting drug membrane permeability, " J. Med. Chem. 38 (1995) 590-594.
57. S. Ong, H. Liu, C. Pidgeon, "Immobilized artificial membrane chromatography: Measurements of membrane partition coefficient and predicting drug permeability, " J. Chromatogr. A 728 (1996) 113-128.
58. D. Rhee, R. Markovich, W.G. Chae, X. Qiu, C. Pidgeon, "Chromatographic surfaces prepared from lysophosphatidylcholine ligands, " Anal. Chim. Acta 297 (1994) 377-386.
59. S. Ong, H. Liu, X. Qiu, G. Bhat, C. Pidgeon, "Membrane partition coefficients chromatographically measured using immobilized artificial membrane surfaces, " Anal. Chem. 67 (1995) 755-762.
60. C. Pidgeon, U.V. Venkataram, "Immobilized artificial membrane chromatography: Supports composed of membrane lipids, " Anal. Biochem. 176 (1989) 36-47.
61. R.J. Markovich, J.M. Stevens, C. Pidgeon, "Fourier transform infrared assessed of membrane lipids immobilized to silica: Leaching and stability of immobilized artificial membrane -bonded phase, " Anal. Biochem. 182 (1989) 237-244.
62. R.J. Markovich, X. Qiu, D.E. Nichols, C. Pidgeon, B. Invergo, F.M. Alvarez, "Silica subsurface amine effect on the chemical stability and chromatographic properties of end-capped immobilized artificial membrane surfaces, " Anal. Chem. 63 (1991) 1851-1860.
63. A. Taillardat-Bertschinger, P.A. Carrupt, F. Barbato, B. Testa, "Immobilized artificial membrane HPLC in drug research, " J. Med. Chem. 46 (2003) 655-665.
64. C. Pidgeon, C. Marcus, F. Alvarez, "Immobilized artificial membrane chromatography: Surface chemistry and applications, " In: J.W. Kelly, T.O. Baldwin (Eds.), Applications of Enzyme Biotechnology, Plenum Press, New York, 1991, pp. 201-220.
65. G.W. Caldwell, J.A. Masucci, M. Evangelisto, R. White, "Evaluation of the immobilized artificial membrane phosphatidylcholine. Drug discovery column for high-performance liquid chromatographic screening of drug-membrane interactions, " J. Chromatogr. A 800 (1998) 161-169.
66. H. Liu, S. Ong, L. Glunz, C. Pidgeon, "Predicting drug-membrane interactions by HPLC: Structural requirements of chromatographic surfaces, " Anal. Chem. 67 (1995) 3550-3557.
67. F. Barbato, G. di Martino, G. Grunetto, M.I. La Rotonda, "Prediction of drug-membrane interactions by IAM-HPLC: Effects of different phospholipid stationary phases on the partition of bases, " Eur. J. Pharm. Sci. 22 (2004) 261-269.
68. Regis Technologies, INC., 8210 Austin Avenue, IL 60053, USA, http://www.registech.com.
69. Q. Sheng, K. Schulten, C. Pidgeon, "Molecular dynamics simulation of immobilized artificial membranes, " J. Phys. Chem. 99 (1995) 11018-11027.
70. D.D. Lasic, Liposomes: From physics to applications, Elsevier, Amsterdam, 1993.
71. C.A. Rimmer, C.R. Simmons, J.G. Dorsey, "The measurement and meaning of void volumes in reversed-phase liquid chromatography, " J. Chromatogr. A 965 (2002) 219-232.
72. A. Taillardat-Bertschinger, A. Galland, P.A. Carrupt, B. Testa, "Immobilized artificial membrane liquid chromatography: Proposed guidelines for technical optimization of retention measurements, " J. Chromatogr. A 953 (2002) 39-53.
73. F. Tsopelas, M. Ochsenkühn-Petropoulou, A. Tsantili- Kakoulidou, "Void volume markers in reversed-phase and biomimetic liquid chromatography, " J. Chromatogr. A 1217 (2010) 2847-2854.
74. F. Tsopelas, A. Tsantili-Kakoulidou, M. Ochsenkühn-Petropoulou, "Biomimetic chro-matographic analysis of selenium species: Application for the estimation of their pharmacokinetic properties, " Anal. Bioanal. Chem. 397 (2010) 2171-2180.
75. M.R. Ledbetter, S. Gutsell, G. Hodges, J.C. Madden, S. O'Connor, M.T.D. Cronin, "Database of published retention factors for immobilized artificial membrane HPLC and an assessment of the effect of experimental variability, " Environ. Toxicol. Chem. 30 (2011) 2701-2708.
76. Y. Marcus, Y. Migron, "Polarity, hydrogen bonding, and structure of mixtures of water and cyanomethane, " J. Phys. Chem. 95 (1991) 400-406.
77. D. Vrakas, D. Hadjipavlou-Litina, A. Tsantili-Kakoulidou, "Retention of substituted coumarins using immobilized artificial membrane (IAM) chromatography: A comparative study with n-octanol partitioning and reversed-phase HPLC and TLC, " J. Pharm. Biomed. Anal. 39 (2005) 908-913.
78. K. Morse, C. Pidgeon, "Importance of mobile phase in immobilized artificial membrane chromatography, " In: B. Testa, H. van de Waterbeemd, G. Folkers, R. Guy (Eds.), Pharmacokinetic Optimization in Drug Research, Verlag Helvetica Chimica Acta, Zürich and Wiley-VCH, Weinheim, 2001, pp. 351-381.
79. M. Hanna, V. de Biasi, B. Bond, P. Camilleri, A. Hutt, "Biomembrane lipids as components of chromatographic phases: Comparative chromatography on coated and bonded phases, " Chromatographia 52 (2000) 710-720.
80. K. Valko, C. Bevan, D. Reynolds, "Chromatographic hydrophobicity index for fast-gradient RP-HPLC: A high-throughput alternative to logP/logD, " Anal. Chem. 69 (1997) 2022-2029.
81. K. Valko, C.M. Du, C.D. Bevan, D.P. Reynolds, M.H. Abraham, "Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: Comparison with other lipophilicity measures, " J. Pharm. Sci. 89 (2000) 1085-1096.
82. S. Ong, C. Pidgeon, "Thermodynamics of solute partitioning into immobilized artificial membranes, " Anal. Chem. 67 (1995) 2119-2128.
83. C. Ottiger, H. Wunderli-Allenspach, "Immobilized artificial membrane (IAM)-HPLC for partition studies of neutral and ionized acids and bases in comparison with the liposomal partition system, " Pharm. Res. 16 (1999) 643-650.
84. A. Taillardat-Bertschinger, F. Barbato, M.T. Quercia, P.A. Carrupt, M. Reist, M.I. La Rotonda, B. Testa, "Structural properties governing retention mechanisms on immobilized artificial membrane (IAM) HPLC columns, " Helv. Chim. Acta 85 (2002) 519-532.
85. F. Barbato, G. diMartino, L. Grumetto, M.I. La Rotonda, "Can protonated beta-blockers interact with biomembranes stronger than neutral isolipophilic compounds? A chromatographic study on three different phospholipid stationary phases (IAM-HPLC), " Eur. J. Pharm. Sci. 25 (2005) 379-386.
86. D. Vrakas, C. Giaginis, A. Tsantili-Kakoulidou, "Different retention behaviour of structurally diverse basic and neutral drugs in immobilized artificial membrane (IAM) and reversed-phase HPLC. Comparison with octanol-water partitioning, " J. Chromatogr. A 1116 (2006) 158-164.
87. D. Vrakas, C. Giaginis, A. Tsantili-Kakoulidou, "Electrostatic interactions and ionization effect in IAM retention. A comparative study with octanol- water partitioning, " J. Chromatogr. A 1187 (2008) 67-78.
88. X. Liu, H. Hefesha, G. Scriba, A. Fahr, "Retention behavior of neutral and positively and negatively charged solutes on an immobilized-artificial-membrane (IAM) stationary phase, " Helv. Chim. Acta 91 (2008) 1505-1512.
89. F. Barbato, I.M. La Rotonda, F. Quaglia, "Chromatogrpahic indexes on immobilized artificial membranes for local anesthetics: Relationships with activity data on closed sodium channels, " Pharm. Res. 14 (1997) 1699-1705.
90. A. Avdeef, "Physicochemical profiling (solubility, permeability and charge state), " Curr. Top. Med. Chem. 1 (2001) 277-351.
91. R. Fruttero, G. Caron, E. Fornatto, D. Boschi, G. Ermondi, A. Gasco, P.A. Carrupt, B. Testa, "Mechanisms of liposomes/water partitioning of (p-methylbenzyl) alkylamines, " Pharm. Res. 15 (1998) 1407-1413.
92. A. Taillardat-Bertschinger, C.A. Marca-Martinet, P.A. Carrupt, M. Reist, G. Caron, R. Fruttero, B. Testa, "Molecular factors influencing retention on immobilized artificial membranes (IAM) compared to partitioning in liposomes and n-octanol, " Pharm. Res. 19 (2002) 729-737.
93. G.P. van Balen, C.A.M. Martinet, G. Caron, G. Bouchard, M. Reist, P.A. Carrupt, R. Fruttero, A. Gasco, B. Testa, "Liposome/water lipophilicity: Methods, information content, and pharmaceutical applications, " Med. Res. Rev. 24 (2004) 299-324.
94. V. Stepanić, D. Žiher, V. Gabelica-Marković, D. Jelić, S. Nunhuck, K. Valko, S. Koštrun, "Physicochemical profile of macrolides and their comparison with small molecules, " Eur. J. Med. Chem. 47 (2012) 462-472.
95. U.M. Hanumegowda, G. Wenke, A. Regueiro-Ren, R. Yordanova, J.P. Corradi, S. P. Adams, "Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds, " Chem. Res. Toxicol. 23 (2010) 749-755.
96. F. Barbato, "The use of immobilized artificial membrane (IAM) chromatography for determination of lipophilicity, " Curr. Comp. Aided Drug Design 2 (2006) 341-352.
97. X. Liu, B. Testa, A. Fahr, "Lipophilicity and its relationship with passive drug permeation, " Pharm. Res. 28 (2011) 962-977.
98. E.C.Y. Chan, W.L. Tan, L.J. Fang, "Modeling Caco-2 permeability of drugs using immobilized artificial membrane chromatography and physicochemical descriptors, " J. Chromatogr. A 1072 (2005) 159-168.
99. M. Genty, G. Gonzalez, C. Clere, V. Desangle-Gouty, J.Y. Legendre, "Determination of passive absorption through the rat intestine using chromatographic indices and molar volume, " Eur. J. Pharm. Sci. 12 (2001) 223-229.
100. A. Nasal, M. Sznitowska, A. Bucinski, R. Kaliszan, "Hydrophobicity parameter from high-performance liquid chromatography on an immobilized artificial membrane column and its relationship to bioactivity, " J. Chromatogr. A 692 (1995) 83-89.
101. F. Barbato, B. Cappello, A. Miro, M.I. La Rotonda, F. Quaglia, "Chromatographic indices on immobilized artificial membranes for the prediction of transdermal transport of drugs, " Il Farmaco 53 (1998) 655-661.
102. N. El Tayar, R.S. Tsai, B. Testa, P.A. Carrupt, A. Leo, "Partitioning of solutes in different solvent systems: The contribution of hydrogenbonding capacity and polarity, " J. Pharm. Sci. 80 (1991) 590-598.
103. J. Kotecha, S. Shah, I. Rathod, G. Subbaiah, "Prediction of oral absorption in humans by experimental immobilized artificial membrane chromatography indices and physicochemical descriptors, " Int. J. Pharm. 360 (2008) 96-106.
104. B.S. Shin, C.H. Yoon, J.P. Balthasar, B.Y. Choi, S.H. Hong, H.J. Kim, J.B. Lee, S.W. Hwang, S.D. Yoo, "Prediction of drug bioavailability in humans using immobilized artificial membrane phosphatidylcholine column chromatography and in vitro hepatic metabolic clearance, " Biomed. Chromatogr. 23 (2009) 764-769.
105. A. Reichel, D.J. Begley, "Potential of immobilized artificial membranes for predicting drug penetration across the blood-brain barrier, " Pharm. Res. 15 (1998) 1270-1274.
106. T. Salminen, A. Pulli, J. Taskinen, "Relationship between immobilized artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs, " J. Pharm. Biomed. Anal. 15 (1997) 469-477.
107. C.H Yoon, S.J. Kim, B.S. Shin, K.C. Lee, S.D. Yoo, "Rapid screening of blood-brain barrier penetration of drugs using the immobilized artificial membrane phosphatidylcholine column chromatography, " J. Biomol. Screen. 11 (2006) 13-20.
108. F. Pehourcq, M. Matoga, B. Bannwarth, "Diffusion of arylpropionatenon-steroidal anti-inflammatory drugs into the cerebrospinal fluid: A quantitative structure-activity relationship approach, " Fundam. Clin. Pharmacol. 18 (2004) 65-70.
109. E. Lazaro, C. Rafols, M.H. Abraham, M. Roses, "Chromatographic estimation of drug disposition properties by means of immobilized artificial membranes (IAM) and C18 columns, " J. Med. Chem. 49 (2006) 4861-4870.
110. T. Peters, All About Albumin: Biochemistry, Genetics and Medical Applications, Academic Press, San Diego, 1996.
111. W.E. Muller, U. Wollert, "Human serum albumin as a 'silent receptor' for drugs and endogenous substances, " Pharmacology 19 (1979) 59-67.
112. K. Williams, E. Lee, "Importance of drug enantiomers in clinical pharmacology, " Drugs 30 (1985) 333-354.
113. F. Jamali, R. Mehvar, F.M. Pasutto, "Enantioselective aspects of drug action and disposition: Therapeutuc pitfalls, " J. Pharm. Sci. 78 (1989) 695-715.
114. I. Petitpas, A.A. Bhattacharya, S. Twine, M. East, S. Curry, "Crystal structure analysis of warfarin binding to human serum albumin: Anatomy of drug site I, " J. Biol. Chem. 276 (2001) 22804-22809.
115. S. Curry, P. Brick, N.P. Franks, "Fatty acid binding to human serum albumin: New insights from crystallographic studies, " Biochim. Biophys. Acta 1441 (1999) 131-140.
116. G. Sudlow, D.J. Birkett, D.N. Wade, "The characterization of two specific drug binding sites on human serum albumin, " Mol. Pharmacol. 11 (1975) 824-832.
117. I. Sjoholm, B. Ekman, A. Kober, I. Ljungstedt-Pahlman, B. Seiving, T. Sjodin, "Binding of drugs to human serum albumin:XI. The specificity of three binding sites as studied albumin immobilized in microparticles, " Mol. Pharmacol. 16 (1979) 767-777.
118. N. Iberg, R. Flückiger, "Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites, " J. Biol. Chem. 261 (1986) 13542-13545.
119. J. Hermansson, M. Eriksson, "Direct liquid chromatographic resolution of acidic drugs using a chiral alpha 1-acid glycoprotein column (Enantiopac), " J. Liq. Chromatogr. 9 (1986) 621-639.
120. J. Hermansson, M. Eriksson, O.J. Nyquist, "Determination of (R)- And (S) disopyramide in human plasma using a chiral alpha 1-acid glycoprotein column, " J. Chromatogr. 336 (1985) 321-328.
121. K. Schmid, In: F.W. Putnam (Ed.), Plasma Proteins, Vol. 1, Academic Press, New York, 1975, p. 184.
122. T. Fournier, N.N. Medjoubi, D. Porquet, "Alpha-1-acid glycoprotein, " Biochim. Biophys. Acta 1482 (2000) 157-171.
123. D.L. Schonfeld, R.B.G. Ravelli, U. Mueller, A. Skerra, "The 1.8-Å crystal structure of α1-acid glycoprotein (orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin, " J. Mol. Biol. 384 (2008) 393-405.
124. I. Fitos, J. Visy, F. Zsila, G. Mády, M. Simonyi, "Selective binding of imatinib to the genetic variants of human α1-acid glycoprotein, " Biochim. Biophys. Acta 1760 (2006) 1704-1712.
125. S. Ongay, C. Neusüß, "Isoform differentiation of intact AGP from human serum by capillary electrophoresis-mass spectrometry, " Anal. Bioanal. Chem. 398 (2010) 845-855.
126. F. Herve, G. Caron, J.-C. Duche, P. Gaillard, N.A. Rahman, A. Tsantili-Kakoulidou, P.-A. Carrupt, P. D'Athis, J.-P. Tilleman, B. Testa, "Ligand specificity of the genetic variants of human alpha-1-acid glycoprotein. Generation of a 3D-QSAR model for drug binding to the A variant, " Mol. Pharmacol. 54 (1998) 129-138.
127. J.K. Lacki, K. Klama, W. Samborski, S.H. Mackiewicz, W. Muller, "Comparison of microheterogeneity of alpha-1-acid-glycoprotein in serum and synovial fluid from rheumatoid arthritis patients, " Clin. Rheumatol. 13 (1994) 598-604.
128. T. Hochepied, F.G. Berger, H. Baumann, C. Libert, "Alpha(1)-acid glycoprotein: An acute phase protein with inflammatory and immunomodulating properties, " Cytokine Growth Factor Rev. 14 (2003) 25-34.
129. L. Budai, O. Ozohanics, K. Ludányi, L. Drahos, T. Kremmer, J. Krenyacz, K. Vékey, "Investigation of genetic variants of α-1 acid glycoprotein by ultra-performance liquid chromatography-mass spectrometry, " Anal. Bioanal. Chem. 393 (2009) 991-998.
130. T. Hochepied, W. Van Molle, F.G. Berger, H. Baumann, C. Libert, "Involvement of the acute phase protein alpha 1-acid glycoprotein in nonspecific resistance to a lethal gram-negative infection, " J. Biol. Chem. 275 (2000) 14903-14909.
131. F. Karush, "The competitive interaction of organic anions with bovine serum albumin, " J. Am. Chem. Soc. 72 (1950) 2714-2718.
132. K.K. Stewart, R.F. Doherty, "Resolution of DL-tryptophan by affinity chromatography on bovine-serum albumin-agarose columns, " Proc. Natl. Acad. Sci. USA 70 (1973) 2850-2852.
133. T.A.G. Noctor, M.J. Diaz-Perez, I.W. Wainer, "Use of a human serum albumin-based stationary phase for high-performance liquid chromatography as a tool for the rapid determination of drug plasma protein binding, " J. Pharm. Sci. 82 (1993) 675-676.
134. P.R. Tiller, I.M. Mutton, S.J. Lane, C.D. Bevan, "Immobilized human serum albumin: Liquid chromatography/mass spectrometry as a method of determining drug-protein binding, " Rapid Commun. Mass Spectrom. 9 (1995) 261-263.
135. E. Domenici, C. Bertucci, P. Salvadori, G. Felix, I. Cahagne, S. Motellier, I.W. Wainer, "Immobilized serum albumin: Rapid HPLC probe of stereoselective protein-binding interactions, " Chromatographia 29 (1990) 170-176.
136. D.S. Hage, J. Austin, "High-performance affinity chromatography and immobilized serum albumin as probes for drug- And hormone-protein binding, " J. Chromatogr. B 739 (2000) 39-54.
137. W.E. Lindup, In: J.W. Bridges, L.F. Chasseaud, G.G. Gibson (Eds.), Progress in Drug Metabolism, Vol. 10, Taylor & Francis, New York, 1987, Chapter 4.
138. T.C. Kwong, "Free drug measurements: Methodology and clinical significance, " Clin. Chim. Acta 151 (1985) 193-216.
139. J. Barre, F. Didey, F. Delion, J.-P. Tillement, "Problems in therapeutic drug monitoring: Free drug level monitoring, " Ther. Drug Monit. 10 (1988) 133-143.
140. B. Loun, D.S. Hage, "Characterization of thyroxine-albumin binding using high-performance affinity chromatography. I. Interactions at the warfarin and indole sites of albumin, " J. Chromatogr. B Biomed. Appl. 779 (1992) 225-235.
141. J. Haginaka, "Protein-based chiral stationary phases for high-performance liquid chromatography enantioseparations, " J. Chromatogr. A 906 (2001) 253-273.
142. V. Tittelbach, M. Jaroniec, R.K. Gilpin, "Synthesis and characterization of silica-immobilized serum albumin stationary phases for HPLC, " J. Liq. Chromatogr. Rel. Technol. 19 (1996) 2943-2965.
143. M.J. Yoo, D.S. Hage, "Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates, " J. Chromatogr. A 1218 (2011) 2072-2078.
144. S. Allenmark, Chromatographic Enantioseparation: Methods and Applications, 2nd ed. Ellis Horwood, New York, 1991, Chapter 7.
145. S. Allenmark, B. Bomgren, H. Boren, "Direct liquid chromatographic separation of enantiomers on immobilized protein stationary phases. III. Optical resolution of a series of N-aroyl D, L-amino acids by high-performance liquid chromatography on bovine serum albumin covalently bound to silica, " J. Chromatogr. 264 (1983) 63-68.
146. P. Erlandsson, I. Marle, L. Hansson, R. Isaksson, C. Petterson, G. Petterson, "Immobilized cellulase (CBH I) as a chiral stationary phase for direct resolution of enantiomers, " J. Am. Chem. Soc. 112 (1990) 4573-4574.
147. K. Harada, Q. Yuan, M. Nakayama, A. Sugii, "Effects of organic modifiers on the chiral recognition by different types of silica-immobilized bovine serum albumin, " J. Chromatogr. A 740 (1996) 207-213.
148. R. Mallik, D.S. Hage, "Development of an affinity silica monolith containing human serum albumin for chiral separations, " J. Pharm. Biomed. Anal. 46 (2008) 820-830.
149. J. Haginaka, T. Murashima, C. Seyama, "Separation of enantiomers on a lysozyme-bonded silica column, " J. Chromatogr. A 666 (1994) 203-210.
150. J. Haginaka, Y. Miyano, Y. Saizen, C. Seyama, T. Murashima, "Separation of enantiomers on a pepsin-bonded column, " J. Chromatogr. A 708 (1995) 161-168.
151. A. Nystrom, A. Strandberg, A. Aspegren, S. Behr, A. Karlsson, "Use of immobilized amyloglucosidase as chiral selector in chromatography. Immobilization and performance in liquid chromatography, " Chromatographia 50 (1999) 209-214.
152. J. Hermansson, "Direct liquid chromatographic resolution of racemic drugs using α1-acid glycoprotein as the chiral stationary phase, " J. Chromatogr. 269 (1983) 71-80.
153. T. Miwa, M. Ichikawa, M. Tsuno, T. Hattori, T. Miyakawa, M. Kayano, Y. Miyake, "Direct liquid chromatographic resolution of racemic compounds. Use of ovomucoid as a column ligand, " Chem. Pharm. Bull. 35 (1987) 682-686.
154. J. Haginaka, C. Seyama, N. Kanasugi, "The absence of chiral recognition ability in ovomucoid: Ovoglycoprotein-bonded HPLC stationary phases for chiral recognition, " Anal. Chem. 67 (1995) 2539-2547.
155. T. Miwa, T. Miyakawa, Y. Miyake, "Characteristics of an avidin-conjugated column in direct liquid chromatographic resolution of racemic compounds, " J. Chromatogr. A 457 (1988) 227-233.
156. N. Mano, Y. Oda, N. Asakawa, Y. Yoshida, T. Sato, "Development of a flavoprotein column for chiral separation by high-performance liquid chromatography, " J. Chromatogr. 623 (1992) 221-228.
157. N. Mano, Y. Oda, N. Asakawa, Y. Yoshida, T. Sato, "Conalbumin-conjugated silica gel, a new chiral stationary phase for high- performance liquid chromatography, " J. Chromatogr. 603 (1992) 105-109.
158. G. Massolini, E. De Lorenzi, D.K. Lloyd, A.M. McGann, G. Caccialanza, "Evaluation of β-lactoglobulin as a stationary phase in high-performance liquid chromatography and as a buffer additive in capillary electrophoresis: Observation of a surprising lack of stereoselectivity, " J. Chromatogr. B 712 (1998) 83-94.
159. R.C. Jewell, K.L.R. Brouwer, P.J. McNamara, "α1-Acid glycoprotein high-performance liquid chromatography column (AnantioPAC) as a screening tool for protein binding, " J. Chromatogr. B Biomed. Appl. 487 (1989) 257-264.
160. G. Schill, I.W. Wainer, S.A. Barkan, "Chiral separations of cationic and anionic drugs on an α 1-acid glycoprotein-bonded stationary phase (enantioPac®). II. Influence of mobile phase additives and pH on chiral resolution and retention, " J. Chromatogr. 365 (1986) 73-88.
161. D.S. Ashton, C.R. Beddell, G.S. Cockerill, K. Gohil, C. Gowrie, J.E. Robinson, M.J. Slater, K. Valko, "Binding measurements of indolocarbazole derivatives to immobilised human serum albumin by high-performance liquid chromatography, " J. Chromatog. B 677 (1996) 194-198.
162. M. Chrysanthakopoulos, C. Giaginis, A. Tsantili-Kakoulidou, "Retention of structurally diverse drugs in human serum albumin chromatography and its potential to simulate plasma protein binding, " J. Chromatogr. A 1217 (2010) 5761-5768.
163. K. Valko, S. Nunhuck, C. Bevan, M.H. Abraham, D.P. Reynolds, "Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol-water and immobilized artificial membrane lipophilicity, " J. Pharm. Sci. 92 (2003) 2236-2248.
164. J. Reilly, D. Etheridge, B. Everatt, Z. Jiang, C. Springer, R.A. Fairhurst, "Studies in drug albumin binding using HSA and RSA affinity methods, " J. Liq. Chromatogr. Relat. Technol. 34 (2011) 317-327.
165. I.M. Chaiken (Ed.), Analytical Affinity Chromatography, CRC Press, Boca Raton, FL, 1987.
166. D.S. Hage, "High performance affinity chromatography: A powerful tool for studying serum protein binding, " J. Chromatogr. B 768 (2002) 3-30.
167. T.A.G. Noctor, D.S. Hage, I.W. Wainer, "Allosteric and competitive displacement of drugs from human serum albumin by octanoic acid, as revealed by high-performance liquid affinity chromatography, on a human serum albumin-based stationary phase, " J. Chromatogr. B Biomed. Appl. 577 (1992) 305-315.
168. T.A.G. Noctor, C.D. Pham, R. Kaliszan, I.W. Wainer, "Stereochemical aspects of ben-zodiazepine binding to human serum albumin. I. Enantioselective highperformance liquid affinity chromatographic examination of chiral and achiral binding interactions between 1, 4-benzodiazepines and human serum albumin, " Mol. Pharm. 42 (1992) 506-511.
169. E. Domeneci, C. Bertucci, P. Salvadori, I.W. Wainer, "Use of a human serum albumin-based high-performance liquid chromatography chiral stationary phase for the investigation of protein binding: Detection of the allosteric interaction between warfarin and benzodiazepine binding sites, " J. Pharm. Sci. 80 (1991) 164-166.
170. D.S. Hage, S.A. Tweed, "Recent advances in chromatographic and electrophoretic methods for the study of drug-protein interactions, " J. Chromatogr. B 699 (1997) 499-525.
171. S. Tweed, B. Loun, D.S. Hage, "Effects of ligand heterogeneity in the characterization of affinity columns by frontal analysis, " Anal. Chem. 69 (1997) 4790-4798.
172. N.I. Nakano, Y. Shimamori, S. Yamaguchi, "Binding capacities of human serum albumin monomer and dimer by continuous frontal affinity chromatography, " J. Chromatogr. 237 (1982) 225-232.
173. C. Lagercrantz, T. Larsson, H. Karlsson, "Binding of some fatty acids and drugs to immobilized bovine serum albumin studied by column affinity chromatography, " Anal. Biochem. 99 (1979) 352-364.
174. B. Loun, D.S. Hage, "Chiral separation mechanisms in protein-based HPLC columns. 1. Thermodynamic studies of (R)- And (S)-warfarin binding to immobilized human serum albumin, " Anal. Chem. 66 (1994) 3814-3822.
175. H. Yoshida, I. Morita, G. Tamai, T. Masujima, T. Tsuru, N. Takai, H. Imai, "Some characteristics of a protein-coated ODS column and its use for the determination of drugs by the direct injection analysis of plasma samples, " Chromatographia 19 (1984) 466-472.
176. F. Barbato, G. di Martino, L. Grumetto, M.I. La Rotonda, "Retention of quinolones on human serum albumin and α1-acid glycoprotein HPLC columns: Relationships with different scales of lipophilicity, " Eur. J. Pharm. Sci. 30 (2007) 211-219.
177. N. Lammers, H. De Bree, C.P. Groen, H.M. Ruijten, B.J. Jong, "Determination of drug protein-binding by high-performance liquid chromatography using a chemically bonded bovine albumin stationary phase, " J. Chromatogr. B Biomed. Appl. 496 (1989) 291-300.
178. A. Nasal, A. Radwanska, K. Osmialowski, A. Bucinski, R. Kaliszan, G.E. Barker, P. Sun, R.A. Hartwick, "Quantitative relationships between the structure of β-adrenolytic and antihistamine drugs and their retention on an α1-acid glycoprotein HPLC column, " Biomed. Chromatrogr. 8 (1994) 125-129.
179. R. Kaliszan, A. Nasal, M. Turowski, "Quantitative structure-retention relationships in the examination of the topography of the binding site of antihistamine drugs on alpha 1-acid glycoprotein, " J. Chromatogr. A 722 (1996) 25-32.
180. H. Xuan, D.S. Hage, "Immobilization of alpha(1)-acid glycoprotein for chromatographic studies of drug-protein binding, " Anal. Biochem. 346 (2005) 300-310.
181. F. Beaudry, M. Coutu, N.K. Brown, "Determination of drug-plasma protein binding using human serum albumin chromatographic column and multiple linear regression model, " Biomed. Chromatogr. 13 (1999) 401-406.
182. G.A. Ascoli, E. Domenici, C. Bertucci, "Drug binding to human serum albumin: Abridged review of results obtained with high-performance liquid chromatography and circular dichroism, " Chirality 18 (2006) 667-679.
183. B. Ravindranath, "In Principles and practice of chromatography, " Ellis Horwood, Chichester, UK, 1989, pp. 149-150.
184. G.A. Ascoli, C. Bertucci, P. Salvadori, "Ligand binding to a human serum albumin stationary phase: Use of same-drug competition to discriminate pharmacologically relevant interactions, " Biomed Chromatogr. 12 (1998) 248-254.
185. F. Tsopelas, M. Ochsenkühn-Petropoulou, A. Tsantili-Kakoulidou, "Exploring the elution mechanism of selenium species on liquid chromatography, " J. Sep. Sci. 34 (2011) 376-384.
186. K. Valko, "HPLC based property measurements of drug discovery compounds to predict in vivo drug distribution and aid lead optimisation, " 1st World Conference on Physico-Chemical Methods in Drug Discovery and Development, 2009, Rovinj, Croatia. http://www.iapchem.org/lectures/Rovinj%202009%20klv%20with%20copyright.pdf.
187. G.R. Wilkinson, "Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination, " In: J.G. Hardman, L.E. Limbird, A.G. Gillman (Eds.), Goodman & Gilman's The Pharmacological Bases of Therapeutics, 10th ed. McGraw-Hill, New York, 2001, pp. 20-22.
188. B.B. Brodie, H. Kurtz, L.J. Schanker, "The importance of dissociation constants and lipid solubility on influencing the passage of drugs into the CSF, " J. Pharmacol. Exp. Ther. 130 (1960) 20-25.
189. F. Hollosy, K. Valko, A. Hersey, S. Nunhuck, G. Keri, C. Bevan, "Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning, " J. Med. Chem. 49 (2006) 6958-6971.